Likewise, rosiglitazone facilitated the increase of infiltrated CD3+ T cells in the tumor while inhibiting the late accumulation of CD11b+ and Gr-1+ myeloid cells to significantly retard tumor growth [197]. This evidence concerns the gene ITGAM and neoplasm.